Bioshet what color did you paint your nails?
Yes, I did buy more yesterday. Who wouldn't when a biotech is trading at 2 times existing revenues plus cash on hand, which has:
1. $100 million in cash;
2. $180 million in existing revenues;
3. Its 5th FDA drug just approved with revenues which will be additive;
4. Has two more NDA's on the way in 2014 one of which is a slam dunk and will dominate a $130 M annual market and the other is likely to generate $200 million plus annually if approved;
5. Is essentially breakeven from an operating cash flow standpoint without regard to drug acquisition costs; and
6. Has many Billion dollar market opportunities in the Pipeline including SPI-2012 which is frontburner in an existing $6 Billion Annual Market.
LOL. From $6.60 UP to $8.90 since May in less than two months is hardly a "daytrading stock".
Also, it is 5 FDA approved drugs. Capistrol-enabled Melphalan will be the 6th.
Great analysis and comments ouch.
I think once SPPI has $250M in stable revenues and any positive SP-2012 or Apaz or SP-1620 or Marq data is released which reflect huge revenue market opportunities, there wil be a buyout offer which will likely be accepted even before there is an FDA approval of those blockbusters. Likely in 2016 sometime and in the $2.5 to $3.5 B range at $40 to $60 PPS.
With an approximate $180 million revenue run rate and CE-Melphalan coming on board in 2015 (which is almost certain), when do you expect SPPI's PPS to be at a mere 6 times revenues and $25 PPS. It would likely only be a mere 8 multiple by year-end.
Is it 2014, 2015 or 2016? TIA
And this is why they are FOS: FACT
Per the SPPI annual report, the presently existing patents for SPI-2012 do NOT expire until 2025 - 2030. Of course, there may very well be other patents filed for along the way for various other indications, uses etc. extending patent protection even beyond 2030.
In addition, SPI-2012 is a "biologic" and is therefore subject to much less, if any, generic "biosimilars" even after 2030 due to the stringent FDA approval requirements for biosimilars and the pricing constraints which require biosimilars to generally charge prices at 65% - 85% of the originator of the drug unlike other types of generics
I thought the Shorts always said that the RACEMIC product was a generic to Fusilev. EVERYONE seems REALLY focused on getting a FUSILEV generic and equivalent. Wonder Why? Lying POS!
1. Shorts can rot in HELL. You are shorting life and investing for death. Period. Godspeed on your journey. There is no ambiguity whatsoever.
2. Most important:
Look up KERX, OREX, DNDN, PCYC, AVNR and whomever else you want. This is a premeditated short attack on biotech premeditated with Janet Yellen. Do you think the author of the SA Article on SPPI knew what was coming? For sure.
Bought today. Bought relentlessly since $6 PPS. Will keep on doing so.
Does anyone have any feel for the likely Phase II SPI data and CE Melphalan filing timeline. What about Apaziquone? Is that December 2014 and what is the likelihood for FASTTRACK status?
OREX 50X revenues
ARNA 40X revenues
KERX 30X revenues
PCYC 17X revenues (although this may be a double opportunity... matrix may be right but too rich for me already)
AVNR 9X revenues
SLXP 8X revenues
SPPI 2X revenues Plus
Going to get tighter and tighter and tighter. Shorts down $13 MILLION in 8 days. Only going to get worse. Upgrades, NDA filings, Phase II results for multi-million Blockbusters, Go-No Go Decisions for Blockbusters, Pipeline development and 14 ongoing separate studies including SPI-1620.
If this is your short play, you are ignorant, stupid and out of your mind with a 2 multiple of existing revenues.
LMAO at you.
1. Have you quadrupled your shares since $6's? They are losing their #$%$ and the Tutes or SPPI can take them apart whenever they want. Watch and learn. What is your hurry.
2. They ain't selling the Company for 3 years anyway and it won't be less than $40 IMO.
3. I could care less whether the PPS is $7 or $10 or $12 right now. Temporary only. Higher is better but that is not the end game. The end game is $3 to $5 Billion.
I would not overstate it. You are a dk. It is that simple. Nothing more, nothing less.
If you are a multi-Billion dollar hedge fund with a high frequency computer trading platforms, you can control the share price of any company you want which has less than a 100 million share float and an average of 1 million to several million shares traded each day. Sell more shares than buyers are buying and buy more than the others are selling and you can DRIVE the pps anywhere you want and control it if you have Blackrock, Goldman and others playing that game. They can hold it where they want it in perpetuity until they take out as much as they want and then let it run and make all the money on the upside.
1. SPPI is currently trading at approximately a mere 2 times existing revenues plus cash on hand.
2. $100 million in cash;
3. Up to $180 million in existing revenues;
4. Its 5th FDA drug just approved with revenues which will be additive. Sales started Monday, 7/21;
5. Has two more NDA's on the way in 2014. Capistrol-Enabled Melphalan is a slam dunk and will dominate a $130 M annual market and the other, Apaziquone, is likely to generate $200 million plus annually if approved for Bladder Cancer;
6. Is essentially breakeven from an operating cash flow standpoint without regard to drug acquisition costs; and
7. Has many Billion dollar market opportunities in the Pipeline including SPI-2012 which is frontburner in an existing $6 Billion Annual Market
Oh, it would be WAY WAY Higher than $40. That is merely $2.5 B market cap which is only 2.5 times $1B in revenues. Check out all the others at 8 to 16 times Revenues.
At $1B in Revenues, SPPI would likely have $500M in earnings which is $8 in Earnings Per Share. What PE Ratio? At a piddly 10 to 15, you are at $80 to $120 PPS.
Not saying it will happen, but there is a reasonable opportunity for SPPI to have $1B in 3 to 5 years given how many shots on goal are upcoming shortly.